1. National Institute for Health and Care Excellence. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258. London: National Institute for Health and Care Excellence; 2012 [cited 2017 Jan 17]. Available from: https://www.nice.org.uk/guidance/ta258.
2. National Institute for Health and Care Excellence. Cetuximab for the first-line treatment of metastatic colorectal cancer. NICE technology appraisal guidance 176. London: National Institute for Health and Care Excellence; 2009 [cited 2017 Jan 17]. Available from: https://www.nice.org.uk/Guidance/TA176.
3. National Institute for Health and Care Excellence. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269. London: National Institute for Health and Care Excellence; 2012 [cited 2017 Jan 17]. Available from: https://www.nice.org.uk/Guidance/TA269.
4. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing;GM Frampton;Nat Biotechnol,2013
5. Validation of a next-generation sequencing assay for clinical molecular oncology;CE Cottrell;J Mol Diagn,2014